<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825875</url>
  </required_header>
  <id_info>
    <org_study_id>J15216</org_study_id>
    <secondary_id>IRB00084971</secondary_id>
    <nct_id>NCT02825875</nct_id>
  </id_info>
  <brief_title>Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer</brief_title>
  <official_title>Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we aim to more precisely define the clinical utility of PSMA imaging across a
      range of clinical indications in men with prostate cancer. To accomplish this, we will make
      the 18F-DCFPyL PET/CT scan available to urologists, medical oncologists, and radiation
      oncologists at Johns Hopkins and survey physicians as to the indication for ordering the
      PET/CT and if a change in management occurred as the result of new information gained from
      the scan. We believe these data will prove critical for planning future studies aimed at
      evaluating the efficacy of this test for improving patient outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician responses to a questionnaire</measure>
    <time_frame>less than 1 year</time_frame>
    <description>The Post-PET/CT questionnaire will determine if the PET/CT scan results in changes to clinical management of patient illness.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>adenocarcinoma of the prostate</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F DCFPyL- Radiopharmaceutica</intervention_name>
    <arm_group_label>adenocarcinoma of the prostate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adenocarcinoma of the prostate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Willingness to signed informed consent

          3. Histologically confirmed adenocarcinoma of the prostate

          4. PSA measurement ≤60 days prior to study enrollment

          5. Completed radiographic evaluation with whole-body bone scan (99mTc-MDP or Na18F) and
             cross-sectional imaging (CT or MRI) of the abdomen and pelvis ≤60 days prior to study
             enrollment

        Exclusion Criteria:

          1. Administered a radioisotope within 5 physical half-lives prior to study enrollment

          2. History of other malignancy diagnosed within the last 5 years (exceptions: low grade
             urothelial carcinoma of the bladder, squamous cell carcinoma or basal cell carcinoma
             of the skin).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gorin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

